(Q40173504)

18 September 2017

68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors (English)

1 reference

18 September 2017

Pettinato C

1

1 reference

18 September 2017

Sarnelli A

2

1 reference

18 September 2017

Di Donna M

3

1 reference

18 September 2017

Civollani S

4

1 reference

18 September 2017

Nanni C

5

1 reference

18 September 2017

Montini G

6

1 reference

18 September 2017

Di Pierro D

7

1 reference

18 September 2017

Ferrari M

8

1 reference

18 September 2017

Marengo M

9

1 reference

18 September 2017

Bergamini C

10

1 reference

18 September 2017

14 September 2007

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

18 September 2017

1 reference

18 September 2017

35

1 reference

18 September 2017

1

1 reference

18 September 2017

72-79

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-007-0587-y

18 September 2017

0 references

cites work

Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-007-0587-Y

Validation of GATE Monte Carlo simulations of the GE Advance/Discovery LS PET scanners.

21 January 2018

1 reference

12 December 2020

Peptide receptor imaging and therapy

1 reference

12 December 2020

Imaging tumors with peptide-based radioligands.

1 reference

12 December 2020

Radiolabelling DOTA-peptides with 68Ga

1 reference

12 December 2020

Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC

1 reference

12 December 2020

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

12 December 2020

Contribution to red marrow absorbed dose from total body activity: a correction to the MIRD method.

1 reference

12 December 2020

Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors

1 reference

12 December 2020

DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals

1 reference

12 December 2020

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

12 December 2020

Method for transforming CT images for attenuation correction in PET/CT imaging.

1 reference

12 December 2020

Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.

1 reference

12 December 2020

Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide

1 reference

12 December 2020

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

12 December 2020

Acquisition protocol considerations for combined PET/CT imaging.

1 reference

12 December 2020

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

1 reference

12 December 2020

PET/CT today and tomorrow

1 reference

12 December 2020

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

1 reference

12 December 2020

Imaging of neuroendocrine tumors

1 reference

12 December 2020

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake

1 reference

12 December 2020

68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5.

1 reference

12 December 2020

Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.

1 reference

12 December 2020

Performance evaluation of the new whole-body PET/CT scanner: Discovery ST.

1 reference

12 December 2020

Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy

1 reference

12 December 2020

(68)Ga-labeled peptides in tumor imaging.

1 reference

12 December 2020

PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas

1 reference

12 December 2020

Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data

1 reference

12 December 2020

10.1007/S00259-007-0587-Y

Identifiers

DOI

1 reference

18 September 2017

1 reference